Biogen (BIIB) Notes Payables (2009 - 2025)

Biogen's Notes Payables history runs 12 years deep, the most recent figure standing at $6.3 billion for Q3 2025.

• In Q3 2025, Notes Payables rose 259.54% year-over-year to $6.3 billion; the TTM figure through Sep 2025 stood at $6.3 billion (up 259.54% YoY), while the FY2024 annual figure was $1.7 billion, down 74.8% from the prior year.
• Notes Payables was $6.3 billion for Q3 2025 at Biogen, up from $1.7 billion in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $7.3 billion in Q2 2022 to a low of $250.0 million in Q1 2024.
• Historically, Notes Payables has averaged $4.2 billion across 5 years, with a median of $6.3 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Notes Payables slumped 74.8% in 2024, then jumped 599.64% in 2025.
• A 5-year view of Notes Payables shows it stood at $999.1 million in 2021, then surged by 528.67% to $6.3 billion in 2022, then climbed by 10.46% to $6.9 billion in 2023, then plunged by 74.8% to $1.7 billion in 2024, then surged by 259.44% to $6.3 billion in 2025.
• The last three Notes Payables figures came in at $6.3 billion (Q3 2025), $1.7 billion (Q1 2025), and $1.7 billion (Q4 2024), per Business Quant data.